Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)

Kelly M. Crowder(Howard Hughes Medical Institute), Sandra Bajjalieh(Howard Hughes Medical Institute), Michael R. Peterson(Howard Hughes Medical Institute), Brian D. Hale(Howard Hughes Medical Institute), Theresa A. Jones(Howard Hughes Medical Institute), Jane M. Gunther(Howard Hughes Medical Institute), Charles Chavkin(University of Washington), Richard H. Scheller(Genesys (United States)), Hai Zhuan Zhang(Howard Hughes Medical Institute)
Proceedings of the National Academy of Sciences
December 21, 1999
10.1073/pnas.96.26.15268
Cited by 415

Related Papers

SNAREs — engines for membrane fusion
|Nature Reviews Molecular Cell Biology|2006|2.6k
A protein assembly-disassembly pathway in vitro that may correspond to sequential steps of synaptic vesicle docking, activation, and fusion
|Cell|1993|1.9k
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
|Nature Biotechnology|2008|1.4k
Syntaxin: A Synaptic Protein Implicated in Docking of Synaptic Vesicles at Presynaptic Active Zones
|Science|1992|1.3k
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
|Nature Biotechnology|2012|997